SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and N

Tivoxavir Marboxil Tablet Bridging Study Completed in Preparation for Additional StudiesNEWTOWN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critic…

TRAW

Related stories